Alefacept, Recombinant human LFA3 protein, Fc tagged
Alefacept, Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3/LFA3) linked to the Fc portion of human IgG1. Expressed in CHO cells, MW is 91.4 kD.
<0.001 EU per 1 μg of the peptide by the LAL method
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 2-8 °C for 1 week. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
As an immunosuppressive drug, The product can be used for treatment of moderate to severe chronic plaque psoriasis.
Interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes.
Target 1. T-cell surface antigen CD2; Target 2. Complement C1r subcomponent; Target 3. Complement C1q subcomponent subunit A; Target 4. Complement C1q subcomponent subunit B; Target 5. Complement C1q subcomponent subunit C; Target 6. Low affinity immunoglobulin gamma Fc region receptor III-A; Target 7. High affinity immunoglobulin gamma Fc receptor I; Target 8. Low affinity immunoglobulin gamma Fc region receptor II-a; Target 9. Low affinity immunoglobulin gamma Fc region receptor II-b; Target 10. Low affinity immunoglobulin gamma Fc region receptor II-c; Target 11. Low affinity immunoglobulin gamma Fc region receptor III-B
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.